RecruitingNot applicableNCT05933174
824
studies recruiting now
as of 7 Sept 2026
11,383
studies registered in total
as of 7 Sept 2026
13
countries with a recruiting site
as of 7 Sept 2026
4 Sept 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 3NCT07533175
AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
RecruitingNot applicableNCT07778121
Screening for Obstructive Sleep Apnea in High-risk Patients in a Danish Rural Population: A Pilot Feasibility Study
RecruitingPhase 1NCT07803809
Phase 1 Clinical Study of MWN105 Injection in Participants With Overweight or Obesity
RecruitingNot applicableNCT07434791
Goal-Directed Therapy to Reduce Kidney and Cardiovascular Risk in Diabetic Kidney Disease (GOLD-STANDARD)
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 824 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new MODY study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About MODY
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations, and the genes involved (ABCC8, CEL, GCK, HNF4A, KCNJ11, KLF11).
Treatments being studied
2 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Phase 2/3Glimepiride (Amaryl)
Phase 2/3Liraglutide (Liraglutide component of xultophy 100/3.6)
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).